GlassScriptPhysician profile
James Pagano
NPI 1396742672
$3,188.25
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $694 · 2021: $1,160 · 2022: $501.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $662.50 | 2019-2022 | |
| Amgen INC. | $532.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $297.47 | 2019-2022 | |
| Medtronic, INC. | $248.13 | 2022 | |
| Esperion Therapeutics, INC. | $233.87 | 2020-2021 | |
| Pfizer INC. | $187.87 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $183.96 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.49 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $102.18 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $88.73 | 2019-2020 | |
| Abbott Laboratories | $78.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $77.71 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $47.05 | 2019 | |
| Novo Nordisk INC | $41.23 | 2022 | |
| Medtronic Vascular, INC. | $38.41 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.71 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $28.01 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.91 | 2021 | |
| Kestra Medical Technology Services, INC. | $25.76 | 2022 | |
| Astellas Pharma US INC | $24.40 | 2020 | |
| Biotronik INC. | $24.03 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.24 | 2021 | |
| Boston Scientific Corporation | $15.83 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.09 | 2019 | |
| Bardy Diagnostics, INC. | $11.09 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pagano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.